Articles tagged "Outcome"

2017 American Transplant Congress
Controlled Donation After Circulatory Death (cDCD) Donors May Become Similar to Brain Death Donors (DBD).
C. Antoine,¹ M. Videcoq,² B. Riou,³ D. Dorez,⁴ G. Cheisson,⁵ L. Martin-Lefèvre,⁶ L. Durand,¹ E. Savoye,¹ G. Karam,² B. Barrou.³
¹Agence de la Biomedecine, Saint Denis La Plaine, France; ²University Hospital, Nantes, France; ³University Hospital La Pitie, Paris, France; ⁴Hospital, Annecy, France; ⁵University Hospital, Kremlin Bicetre, France; ⁶Hospital, La Roche Sur Yon, France
Since 2014 in France, we started a cDCD program characterized by the introduction of normothermia regional perfusion (nRP) and selection criteria as donor age ≤65…
2017 American Transplant Congress
Proposal for HCC Exception Points to Match Drop Out Risk.
H. Yeh,³ M. Akan,¹ N.-H. Leung,² J. Markmann,³ S. Tayur.¹
¹CMU, Pittsburgh; ²City U, Hong Kong, Hong Kong; ³MGH, Boston
Background: Recent changes in HCC exception point policy aims to equalize wait list outcomes between HCC and non-HCC patients, but remains dissociated from tumor biology.…
2017 American Transplant Congress
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.
S. Rhazouani,^1,4 S. Anwar,² D. Brennan,¹ K. Lentine,³ K. Venkatachalam,¹ A. Malone,¹ T. Alhamad.¹
¹Washington University, Saint Louis; ²Freman Hospital, New Castle, United Kingdom; ³Saint Louis University, Saint Louis; ⁴Cleveland Clinic Foundation, Weston
Background: Hydroxychloroquine, also known as Plaquenil ( PLQ) is an antimalarial drug with immunomodulatory action. Recent studies have demonstrated a protective effect of PLQ in…
2017 American Transplant Congress
Trends in Long-Term Outcomes of Kidney Transplantation in Australia and New Zealand.
W. Lim,¹ W.-C. Yeung,² S. Campbell,³ S. Chadban,⁴ P. Clayton,⁵ C. Hawley,³ D. Johnson,³ S. McDonald,⁵ E. Pascoe,⁶ G. Wong,⁷ S. Badve.²
¹Sir Charles Gairdner Hospital, Perth, Australia; ²St George Hospital, Sydney, Australia; ³Princess Alexandra Hospital, Brisbane, Australia; ⁴Royal Prince Alfred Hospital, Sydney, Australia; ⁵University of Adelaide, Adelaide, Australia; ⁶University of Queensland, Brisbane, Australia; ⁷Westmead Hospital, Sydney, Australia
Introduction: Surgical and medical advances have led to considerable improvement in short-term outcomes of kidney transplantation, with 1-year graft and patient survival approaching 100%. However,…
2017 American Transplant Congress
20 and 25-Year Outcomes Following Pediatric Liver Transplantation.
W. Andrews,¹ N. Gupta,² U. Ekong.³
¹Ped. Surgery, Children's Mercy Hospital, Kansas City, MO; ²Div. Peds. Gastro., Emory, Atlanta, GA; ³Div. Peds. Gastro., Yale, New Haven, CT
Background: Improved 1,5, & 10- year survival following Pediatric Liver Transplantation (LT) has been demonstrated. However 20 and 25-year patient and graft outcomes (including cause…
2017 American Transplant Congress
Cumulative Deficits Frailty Index for Transplant Candidates Predicts Candidacy for Solid Organ Transplantation.
R. Varughese,^1,2 O. Theou,³ X. Huang,¹ O. Famure,¹ Y. Li,¹ N. Chowdhury,¹ E. Renner,^1,2 J. Kim,^1,2 J. MacIver,^1,5 S. Mathur,⁴ K. Rockwood,³ L. Singer.^1,2
¹Toronto Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada; ²Department of Medicine, University of Toronto, Toronto, ON, Canada; ³Department of Medicine, Dalhousie University, Halifax, NS, Canada; ⁴Department of Physical Therapy, University of Toronto, Toronto, ON, Canada; ⁵Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
Introduction: Frailty is a clinical state associated with decreased function and increased vulnerability to physiologic stressors, leading to adverse medical outcomes. The cumulative deficits model…
2017 American Transplant Congress
Living Kidney Donor Pharmaceutical Care Needs Identified Through Linked Transplant Registry and Pharmacy Claims Data.
K. Lentine,¹ S. Gustafson,² M. Schnitzler,¹ G. Hess,³ D. Segev,⁴ A. Garg,⁵ N. Lam,⁶ D. Axelrod,⁷ D. Brennan,⁸ H. Randall,¹ B. Kasiske.⁹
¹St Louis Univ, St Louis, MO; ²SRTR, Minneapolis, MN; ³Symphony Health, Philadelphia, PA; ⁴Johns Hopkins, Baltimore, MD; ⁵Western Univ, London, Canada; ⁶Univ Alberta, Edmonton, AB, Canada; ⁷E Carolina Univ, Greenville, NC; ⁸Washington Univ, St. Louis, MO
Limited data are available on pharmaceutical care needs of living kidney donors (LKD).We integrated 1) national US Scientific Registry of Transplant Recipients data for LKD…
2017 American Transplant Congress
Risk Factors of Treatment Failure in Antibody Mediated Rejection.
V. Pernin,¹ I. Szwarc,¹ T. Kanouni,² V. Garrigue,¹ J. Serre,¹ S. Delmas,¹ G. Mourad,¹ M. Le Quintrec.¹
¹Department of Nephrology, Dialysis and Transplantation, CHU Lapeyronie, Montpellier, France; ²Department of Hematology, CHU St ELoi, Montpellier, France
Background: Antibody-mediated rejection (AMR) is recognized as the major cause of kidney allograft loss. Despite an aggressive treatment, prognosis is usually poor. The aim of…
2017 American Transplant Congress
Prospective Monitoring of De Novo Donor-Specific Antibodies: Incidence, Clinical Outcomes and Dynamic Changes Over 5 Years After Kidney Transplantation.
M. Ajaimy, A. Colovai, N. Hayde, J. Graham, M. Lubetzky, L. Kamal, G. De Bocardo, E. Akalin.
Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, Bronx
Background: We aimed to investigate the incidence and dynamic changes of de novo donor-specific-antibodies (dnDSA) after kidney transplantation and clinical outcomes.Methods: This is a prospective…
2017 American Transplant Congress
Incidence and Outcomes of Re-Explorations in Living Donor Liver Transplantation.
V. Varma, S. Sable, S. Kapoor, A. Chauhan, V. Kumaran.
Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
Introduction: Re-exploration in Living Donor Liver Transplantation(LDLT) is required in patients for various causes, bleeding being the commonest cause. The outcome of these patients is…